HXM en es it fr

HXM Brand names, HXM Analogs

HXM Brand Names Mixture

  • No information avaliable

HXM Chemical_Formula


HXM RX_link


HXM fda sheet


HXM msds (material safety sheet)

HXM Synthesis Reference

No information avaliable

HXM Molecular Weight

210.28 g/mol

HXM Melting Point

172-174 oC

HXM H2O Solubility

91 mg/L

HXM State




HXM Dosage Forms


HXM Indication

For use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.

HXM Pharmacology

Altretamine is a novel antineoplastic agent. The precise mechanism by which altretamine exerts its cytotoxic effect is unknown, although a number of theoretical possibilities have been studied. Structurally, altretamine resembles the alkylating agent triethylenemelamine, yet in vitro tests for alkylating activity of altretamine and its metabolitics have been negative. Altretamine has been demonstrated to be efficacious for certain ovarian tumors resistant to classical alkylating agents. Metabolism of altretamine is a requirement of cytotoxicity. Synthetic monohydroxymethylmelamines, and products of altretamine metabolism, in vitro and in vivo, can form covalent adducts with tissue macromolecules including DNA, but the relevance of these reactions to antitumor activity is unknown.

HXM Absorption

No information avaliable

HXM side effects and Toxicity

No information avaliable

HXM Patient Information

No information avaliable

HXM Organisms Affected

Humans and other mammals